RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

Nothing matters here but how potential partners perceive the results of the RD trials. Of course, the more ambiguous the results the harder to infer BP reaction, but if the data look good, then short-term share-price fluctuations are background noise. This stock will go up eventually, and this increase will be independent of regulatory or scientific binary events (pace RD-1).

I hope for all of us that we're not disappointed tomorrow.